Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Glioblastoma multiforme (GBM) is an aggressive intracranial tumor characterized by local and distant brain relapse despite aggressive therapy. Current standard treatment includes surgical resection followed by radiation with concurrent and adjuvant temozolomide as part of a combined modality approach. In this review, the historical basis for the current standard treatment is discussed as well as other recent combined modality successes and failures. An overview of emerging combined modality therapies for GBM is presented including immunotherapy, and rationally designed radiosensitizers. Unanswered questions facing the oncology community regarding the treatment of GBM are also discussed.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT.
Christopher D
CD
Corso
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT. Electronic address: Ranjit.bindra@yale.edu.
Ranjit S
RS
Bindra
D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods / Q000639:trends; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008495:Medical Oncology; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016896:Treatment Outcome
D011838:Radiation-Sensitizing Agents